Skip to main content
null
JHEOR
  • Menu
  • Articles
    • Author Correction
    • Autoimmune Diseases
    • Brief Report
    • Cardiovascular Conditions
    • Commentary
    • Correspondence
    • Dermatological Diseases
    • Endocrine Diseases
    • Gastrointestinal Conditions
    • General Indications
    • Genetic Disorders
    • Hematology
    • Infectious Diseases
    • Methodology and Healthcare Policy
    • Musculoskeletal Conditions
    • Nephrologic/Hepatologic Conditions
    • Neurological Disorders
    • Oncology
    • Ophthalmology
    • Other Conditions
    • Perspective
    • Psychological Conditions
    • Respiratory Diseases
    • Trauma Induced Conditions
    • Urological/Gynecological Diseases
    • All
  • For Authors
  • Editorial Board
  • About
  • Issues
  • Blog
  • Journal Policies
  • For Reviewers
  • search

RSS Feed

Enter the URL below into your favorite RSS reader.

http://localhost:48312/feed
Oncology
Vol. 3, Issue 2, 2016October 21, 2015 EDT

Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy

Gabriel Tremblay, Unnati Majethia, Ilias Kontoudis, Jesús De Rosendo,
spaincost-utilitycost-effectivenesseribulinher2-negativemetastatic breast cancer
Copyright Logoccby-4.0 • https://doi.org/10.36469/9834
Photo by Ken Treloar on Unsplash
JHEOR
1.
Tremblay G, Majethia U, Kontoudis I, De Rosendo J. Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy. JHEOR. 2015;3(2):180-193. doi:10.36469/​9834
Save article as...▾

View more stats

This website uses cookies

We use cookies to enhance your experience and support COUNTER Metrics for transparent reporting of readership statistics. Cookie data is not sold to third parties or used for marketing purposes.

Powered by Scholastica, the modern academic journal management system